Microdosing psychedelics : Motivations, subjective effects and harm reduction Toby Lea, Nicole Amada, Henrik Jungaberl, Henrike Schecke, Michael Klein International Journal of Drug Policy, 2020, 75, 102600, 9 p. Doi : 10.1016/j.drugpo.2019.11.008 A B S T R A C T Background : In recent years there has been growing media attention on microdosing psychedelics (e.g., LSD, psilocybin). This refers to people routinely taking small doses of psychedelic substances to improve mental health and wellbeing, or to enhance cognitive performance. Research evidence is currently limited. This paper examines microdosing motivations, dosing practices, perceived short-term benefits, unwanted effects, and harm reduction practices. Methods : An international online survey [...]
Lire la suitePersisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic psychedelic Use : An Online Survey Albert Garcia-Romeu, Alan K. Davis, Earth Erowid, Fire Erowid, Roland R. Griffiths and Matthew W. Johnson Frontiers in Psychiatry, 2020, Vol 10, Article 955. Doi : 10.3389/fpsyt.2019.00955 Background : Observational data and preliminary studies suggest serotonin 2A agonist psychedelics may hold potential in treating a variety of substance use disorders (SUDs), including opioid use disorder (OUD). Aims : The study aim was to describe and analyze self-reported cases in which naturalistic psychedelic use was followed by cessation or reduction in other substance use. Methods : An anonymous online survey of [...]
Lire la suiteMarijuana Use Continues to Grow in Older Adults Pauline Anderson Medscape, February 26, 2020 https://www.medscape.com/viewarticle/925762?nlid=134178_2052&src=WNL_mdplsnews_200228_mscpedit_psyc&uac=292598PZ&spon=12&impID=2294726&faf=1 Cannabis use in older Americans is growing. New research shows that over a 4-year period use of the drug in individuals age 65 and older increased by 75%. Joseph J. Palamar, PhD, MPH This population is especially vulnerable to potential adverse effects from cannabis and so this population needs to understand the potential risks associated with marijuana use, study investigator Joseph J. Palamar, PhD, MPH, associate professor, Department of Population Health, New York University (NYU) Langone Medical Center, New York City, told Medscape Medical News. The findings, he added, indicate a need for more [...]
Lire la suiteQue (Devrait-on) Savoir sur la Pharmacologie du Cannabidiol ? Article rédigé par les Centres d’Addictovigilance de Grenoble, Marseille, Paris Addictovigilance, Bulletin de l’Association des Centres d’Addictovigilance, 2020, 13. www.addictovigilance.fr Messages clefs Les phyto-cannabinoïdes et les cannabinoïdes de synthèse ont des effets très variés,utiles à caractériser d’un point devue pharmacologique pour mieux préciser les effets de chacun et leurs éventuelles interactions chez l’Homme, a fortiori dans un contexte de large diffusion. Le cannabidiol (CBD) est l’un des principaux phyto-cannabinoïdes présent dans Cannabis sativa, avec le tétrahydrocannabinol (THC). Le CBD a une action pléiotropique notamment sur les récepteurs à la sérotonine, à la dopamine et pas ou très peu [...]
Lire la suiteAssociation Between Recreational Marijuana Legalization in the United States and Changes in Marijuana Use and Cannabis Use Disorder From 2008 to 2016 Magdalena Cerdá, DrPH; Christine Mauro, PhD; Ava Hamilton, BA; Natalie S. Levy, MPH; Julián Santaella-Tenorio, DrPH; Deborah Hasin, PhD; Melanie M.Wall, PhD; Katherine M. Keyes, PhD; Silvia S. Martins, MD, PhD JAMA Psychiatry, 2019. doi : 10.1001/jamapsychiatry.2019.3254 IMPORTANCE : Little is known about changes in marijuana use and cannabis use disorder (CUD) after recreational marijuana legalization (RML). OBJECTIVES : To examine the associations between RML enactment and changes in marijuana use, frequent use, and CUD in the United States from 2008 to 2016. DESIGN, SETTING, AND [...]
Lire la suiteAssociations Between Marijuana Use and Cardiovascular Risk Factors and Outcomes : A Systematic Review Divya Ravi, MD, MPH; Mehrnaz Ghasemiesfe, MD; Deborah Korenstein, MD; Thomas Cascino, MD; and Salomeh Keyhani, MD, MPH Annals of Internal Medicine, 2018, 168, (3), 187-194. doi : 10.7326/M17-1548 Annals.org Abstract Background : Marijuana use is increasing in the United States, and its effect on cardiovascular health is unknown. Purpose : To review harms and benefits of marijuana use in relation to cardiovascular risk factors and clinical outcomes. Data Sources : PubMed, MEDLINE, EMBASE, PsycINFO, and the Cochrane Library between 1 January 1975 and 30 September 2017. Study Selection : Observational studies that were published [...]
Lire la suite'Standard THC units': a proposal to standardize dose across all cannabis products and methods of administration T.P. Freeman, V.Lorenzetti Addictions, 2019, Oct 12. doi : 10.1111/add.14842 © 2019 Society for the Study of Addiction. Abstract BACKGROUND AND AIMS : Cannabis products are becoming increasingly diverse, and vary considerably in concentrations of ∆9 -tetrahydrocannabinol (THC) and cannabidiol (CBD). Higher doses of THC can increase the risk of harm from cannabis, while CBD may partially offset some of these effects. Lower Risk Cannabis Use Guidelines currently lack recommendations based on quantity of use, and could be improved by implementing standard units. However, there is currently no consensus on [...]
Lire la suiteCannabis : saurez-vous bien faire la distinction entre le «bien-être» et la «récréation» ? Jean-Yves NAU Blog Le Monde, 23 décembre 2019 Bonjour Est-ce une nouvelle tentative pour dépénaliser/légaliser une substance illicite mais très largement consommée ? L’Assemblée nationale vient de créér une « Mission d’information commune sur la réglementation et l’impact des différents usages du cannabis ». Une mission composée de trente-trois députés et issue des réflexions de … six commissions (affaires économiques, affaires sociales, lois, finances, affaires culturelles et éducatives, développement durable). Pourquoi développer une telle énergie législative ? Parce qu’ « en France la réglementation des usages du cannabis a particulièrement évolué ces dix dernières années » [il s’agit de [...]
Lire la suiteEmerging from the dark side : new therapeutic applications of scheduled psychoactive substances Edward James, Thomas L Robertshaw & Andrew D Westwell Future Medical Chemistry, 2019 Doi : 10.4155/fmc-2018-0447 C - ISSN 1756-8919 “Public and mainstream scientific perceptions of these substances are shifting, and it is not difficult to envision a future in which MDMA and psilocybin play a role in contemporary medicine.” Keywords : harm reduction • healthcare • MDMA • positive psychology • psilocybin • psychoactive • psychotherapy The discovery and development of new medicines occupies years of painstaking and expensive scientific work, with multidisciplinary teams working together in the hope of developing a [...]
Lire la suiteCBD & Cannabis Dosage Guide Martin A. Lee On May 16, 2018 (Updated on April 1, 2019) https://www.projectcbd.org/how-to/cbd-dosage-guide High dose? Low dose? CBD? THC? Optimizing one's therapeutic use of cannabis may take some experimentation. It can be relatively easy to experience medical benefits from cannabis. A puff or two of tetrahydrocannabinol (THC)-rich flower can do the trick for a lot of people. Smoking marijuana, however, is not the be-all and end-all of cannabis therapeutics. There are many ways to experience the medical benefits of cannabis, and some of them are even non-intoxicating. In recent years, the advent of potent cannabis oil concentrates, non-intoxicating cannabidiol (CBD) products, [...]
Lire la suite